RxDoctor Payments Data

Rebecca Cutchin

Adult Health · Lafayette, INNPI 1790935146

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,662 of the $3,341 with a category attached, or 79.7%. It is spread thinly across 44 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,539 and has fallen 87.5% since, to $192 in 2025.

$3,341in general payments, 2019–2025

Across 129 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$337
  • AstraZeneca$290
  • Johnson & Johnson$283
  • Pharmacyclics LLC, An Abbvie Company$220
  • E.r. Squibb & Sons, L.L.C.$169
  • Seagen Inc.$151
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$2,66280%
  • Education$67920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,341 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$95,882
Medicare patients
152
Services billed
5,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib14$172,180
EliquisApixaban15$9,528
Dexlansoprazole DrDexlansoprazole11$1,816
Anastrozole78$1,187
Hydroxyurea12$396
Omeprazole13$285
Tamoxifen Citrate13$258
Potassium Chloride18$208
Escitalopram Oxalate11$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$220$172,18014 claims
PfizerEliquis$119$9,52815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.

Other adult health in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →